Stevanato Group (NYSE:STVN) Given New $20.00 Price Target at Citigroup

Stevanato Group (NYSE:STVN) had its target price lowered by equities research analysts at Citigroup from $26.00 to $20.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Several other analysts have also weighed in on the company. UBS Group initiated coverage on Stevanato Group in a report on Wednesday, September 9th. They issued a “neutral” rating and a $23.00 price objective for the company. Weiss Ratings upgraded shares of Stevanato Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, August 27th. William Blair downgraded Stevanato Group from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Stevanato Group in a research note on Wednesday, October 7th. They issued a “hold” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy”.

Stevanato Group Stock Down 5.8%

STVN traded down €0.81 during trading hours on Wednesday, reaching €13.29. 4,406,560 shares of the stock traded hands, compared to its average volume of 533,914. The firm’s fifty day simple moving average is €20.35 and its two-hundred day simple moving average is €18.11. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.61 and a quick ratio of 1.08. The company has a market cap of $4.02 billion, a price-to-earnings ratio of 23.72, a PEG ratio of 1.62 and a beta of 0.80. Stevanato Group has a fifty-two week low of €12.05 and a fifty-two week high of €27.00.

Stevanato Group (NYSE:STVN) last announced its earnings results on Tuesday, November 3rd. The company reported €0.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.17 by (€0.01). Stevanato Group had a return on equity of 10.43% and a net margin of 10.99%. The business had revenue of €326.06 million for the quarter. As a group, analysts forecast that Stevanato Group will post 0.69 earnings per share for the current fiscal year.

Insider Activity

In other Stevanato Group news, Director Luciano Santel sold 2,023 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of €20.09, for a total value of €40,642.07. Following the transaction, the director owned 4,739 shares in the company, valued at approximately €95,206.51. This represents a 29.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Elisabetta Magistretti sold 2,045 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of €20.09, for a total transaction of €41,084.05. Following the completion of the transaction, the director owned 2,930 shares in the company, valued at approximately €58,863.70. This represents a 41.11% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 21,926 shares of company stock worth $459,738.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP bought a new stake in Stevanato Group in the second quarter worth approximately $22,621,000. Ranger Investment Management L.P. acquired a new stake in shares of Stevanato Group in the second quarter valued at about $21,438,000. Schwartz Investment Counsel Inc. increased its position in Stevanato Group by 15.0% in the 3rd quarter. Schwartz Investment Counsel Inc. now owns 661,136 shares of the company’s stock worth $13,871,000 after buying an additional 86,385 shares during the period. Fenimore Asset Management Inc bought a new position in Stevanato Group during the third quarter worth $12,212,000. Finally, Cooper Investors PTY Ltd. raised its position in shares of Stevanato Group by 4.4% during the second quarter. Cooper Investors PTY Ltd. now owns 668,494 shares of the company’s stock valued at $12,080,000 after buying an additional 28,265 shares during the last quarter.

Stevanato Group News Summary

Here are the key news stories impacting Stevanato Group this week:

• Positive Sentiment: Third-quarter revenue rose 8% to €326.1 million, providing evidence of continued growth in the business. Stevanato Group Q3 results
• Neutral Sentiment: A Yahoo Finance analysis argues STVN could be 42% undervalued following the earnings report. This is an analyst valuation view, not a company forecast, and contrasts with more cautious broker actions. Valuation analysis
• Negative Sentiment: Management expects only low-single-digit growth in 2027, citing lower GLP-1 syringe volumes associated with one customer. This outlook appears to have overshadowed Q3 revenue growth and contributed to the sharp prior-session selloff. 2027 outlook
• Negative Sentiment: UBS cut its price target to $16 from $23 while retaining a Neutral rating, and William Blair downgraded the stock from Outperform to Market Perform—signs of reduced analyst confidence. UBS target change William Blair downgrade
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations following the November 3 disclosure and share-price decline. These are investigations, not findings of wrongdoing, but may add headline risk. Securities investigation announcement

Stevanato Group Company Profile

Stevanato Group S.p.A. is an Italy-based provider of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and healthcare industries. Founded in 1949, the company has developed from a glass-packaging manufacturer into an integrated supplier serving customers throughout the global pharmaceutical supply chain.

The company manufactures primary packaging products, including glass vials, syringes, cartridges and ampoules, as well as components and systems used to contain and administer injectable medicines.